

**This policy applies to the following:**

	Standard Control (SF)		Value (VF)		ACSF Chart (ACSF)	✓	Medical Benefit		Medicare Part B	Reference # 4940-D
	Preferred Drug Plan Design (PDPD)		Managed Medicaid Template (MMT)		SF Chart (SFC)		Medical Benefit: Biosimilars First		Medicare Part B: Biosimilars First	
	Advanced Control Specialty (ACSF)		Marketplace (MF)		VF Chart (VFC)		Medical Benefit: Add-on		Medicare Part B: Add-on	
	Balanced (BF)		New to Market (NTM)		IVL		Medical Benefit: Managed Medicaid		Aetna Health Exchange (AHE)	

## EXCEPTIONS CRITERIA INFLIXIMAB

### PREFERRED PRODUCT: INFLECTRA

#### POLICY

This policy informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

#### I. PLAN DESIGN SUMMARY

This program applies to the infliximab products specified in this policy. Coverage for targeted products is provided based on clinical circumstances that would exclude the use of the preferred product and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to all members requesting treatment with a targeted product.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

**Table. Infliximab Products**

Preferred*	Product(s)
Preferred*	<ul style="list-style-type: none"> <li>• <b>Inflectra</b> (infliximab-dyyb)</li> </ul>
Targeted	<ul style="list-style-type: none"> <li>• <b>Avsola</b> (infliximab-axxq)</li> <li>• <b>Remicade</b> (infliximab)</li> <li>• <b>Renflexis</b> (infliximab-abda)</li> </ul>

\*: Medications considered formulary or preferred on your plan may still require a clinical prior authorization review.

#### II. EXCEPTION CRITERIA

Coverage for a targeted product is provided when the member has had a documented intolerable adverse event to the preferred product, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.

#### REFERENCES

1. Avsola [package insert]. Thousand Oaks, CA: Amgen; September 2021.
2. Inflectra [package insert]. New York, NY: Pfizer Inc; June 2021.
3. Remicade [package insert]. Horsham, PA: Janssen Biotech, Inc.; May 2020.
4. Renflexis [package insert]. Whitehouse Station, NJ. Merck & Co., Inc; February 2021.